Savara Inc
Closed
SectorHealthcare
4.74
Overview
Share price change
24h
Min
4.61
Max
4.8100000000000005
Income | -2.9M -40M |
|---|---|
EPS | -0.16 |
Employees | 70 |
EBITDA | -2.9M -40M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +137.1% upside |
Next Earnings | 10 lis 2026 |
|---|
Market Cap | -182M 992M |
|---|---|
Previous open | 4.74 |
Previous close | 4.74 |
Savara Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Savara Inc Forecast
Price Target
By TipRanks
137.1% upside
12 Months Forecast
Average 11.333 USD 137.1%
High 16 USD
Low 9 USD
Based on 6 Wall Street analysts offering 12 month price targets forSavara Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.